Argipressin (Vasopressin) |
| Catalog No.GC30764 |
Arginine-vasopressin, as an important hormone in the regulation of plasma osmolality and blood volume/pressure, always is used in the treatment of septic shock and decompensated cirrhosis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 113-79-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Arginine-vasopressin, as an important hormone in the regulation of plasma osmolality and blood volume/pressure, always is used in the treatment of septic shock and decompensated cirrhosis.[1]
In vitro experiment it shown that treatment with 5-10 µM argipressin (vasopressin) in RN46A cells decreased RN46A proliferation, while 10 µM argipressin (vasopressin) decreased the number of cells extending neurites. [2] In vitro, treatment with 0.1 µM and 1 µM. argipressin (vasopressin)in PV cardiomyocytes, there had a faster dose dependent beating rate than control PV cardiomyocytes by 4 and 37% respectively. [3] In vitro, Arginine vasopressin (10-12M-10-6M) can induce markedly concentration-dependent increases of insulin release from both rodent and human beta-cells, as well as mouse islets.[4] Moreover, treatment with 100 pM to 1 µM Arginine-vasopressin in the non-neuronal cells evoked [Ca2+](i) responses and had concentration-dependent responses increased with days in vitro in culture, reaching a maximum amplitude after 4-5 day. [5]
In vivo efficacy test it exhibited that argipressin (vasopressin) shown antinociception in the hot-plate test after intracerebroventricular injection (0.5 ug) and in the acetic acid abdominal constriction test after intraperitoneal injection (0.1 mg/kg).[6] In vivo experiment it demonstrated that treatment with 0.5 u/kg arginine vasopressin intravenously significantly increased the levels of IL-6 mRNA in rat hearts with the maximum level occurred at 6 h.[7]
References:
[1] Wagener G, Bakker J. Vasopressin in cirrhosis and sepsis: physiology and clinical implications. Minerva Anestesiol. 2015 Dec;81(12):1377-83. Epub 2014 Nov 11.
[2] Marinova Z, et al. Effects of oxytocin and Argipressin (Vasopressin) on the proliferation and differentiation of a serotonergic cell line. J Neural Transm (Vienna). 2018 Jan;125(1):103-106.
[3] Huang JH, et al. Argipressin (Vasopressin) modulates electrical activity and calcium homeostasis in pulmonary vein cardiomyocytes. J Biomed Sci. 2019 Sep 17;26(1):71.
[4] Mohan S, et al. Vasopressin receptors in islets enhance glucose tolerance, pancreatic beta-cell secretory function, proliferation and survival. Biochimie. 2019 Mar;158:191-198.
[5] Moriya T, et al. Vasopressin-induced intracellular Ca²⁺ concentration responses in non-neuronal cells of the rat dorsal root ganglion. Brain Res. 2012 Nov 5;1483:1-12.
[6] Hart SL, Oluyomi AO. Vasopressin and stress-induced antinociception in the mouse. Br J Pharmacol. 1990 Feb;99(2):243-6.
[7] Sun SZ, et al. β-Arrestin 2 mediates Argipressin (Vasopressin)-induced IL-6 induction via the ERK1/2-NF-κB signal pathway in murine hearts. Acta Pharmacol Sin. 2020 Feb;41(2):198-207.
| Cell experiment [1]: | |
Cell lines | PV cardiomyocytes |
Preparation Method | For the measurement of SR Ca2+ leak, PV cardiomyocytes were incubated with argipressin (vasopressin)(1 µM) or Argipressin (Vasopressin)(1 µM) plus KN-93 (a Ca2+/calmodulin-dependent protein kinase II, CaMKII inhibitor, 1 µM) for 4~6 h before experiments. |
Reaction Conditions | 1 µM; 4~6 h |
Applications | Spontaneous Ca2+ transients in argipressin (vasopressin) (1 µM)-treated PV cardiomyocytes were smaller than those in the control by 67%. Argipressin (Vasopressin)(1 µM)-treated PV cardiomyocytes had greater Ca2+ leak than the control, which was attenuated by the presence of KN-93 (1 µM). |
| Animal experiment [2]: | |
Animal models | Rats |
Dosage form | 1.0 or 5.0 ug/kg; s.c. |
Preparation method | Rats were injected with a single subcutaneous dose of either saline, argipressin (vasopressin) (1.0 or 5.0 ug/kg), or an argipressin (vasopressin) analog with only weak endocrinological activity, des-gly-argipressin vasopressin ( 1.0, 5.0 or 10.0 ug/kg). Additional extinction trials were conducted at 2, 4, 6 and 8 h post-injection. |
Applications | Argipressin (Vasopressin) potentiated this radial maze extinction behavior while DG-AVP produced behavioral results directionally opposite to those predicted by a memory facilitation hypothesis. In a subsequent experiment, vasopressin had no effects on unconditioned locomotor activity measured 2 and 4 h post-injection. |
References: | |
| Cas No. | 113-79-1 | SDF | |
| Canonical SMILES | Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bridge: Cys1-Cys6) | ||
| Formula | C46H65N15O12S2 | M.Wt | 1084.23 |
| Solubility | Water : ≥ 360 mg/mL (332.03 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 922.3 μL | 4.6116 mL | 9.2231 mL |
| 5 mM | 184.5 μL | 922.3 μL | 1.8446 mL |
| 10 mM | 92.2 μL | 461.2 μL | 922.3 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *